Cargando…

The peroxisome proliferator-activated receptor gamma (PPARγ) agonist, rosiglitazone, ameliorates neurofunctional and neuroinflammatory abnormalities in a rat model of Gulf War Illness

BACKGROUND: Gulf War (GW) Illness (GWI) is a debilitating condition with a complex constellation of immune, endocrine and neurological symptoms, including cognitive impairment, anxiety and depression. We studied a novel model of GWI based on 3 known common GW exposures (GWE): (i) intranasal lipopoly...

Descripción completa

Detalles Bibliográficos
Autores principales: Keledjian, Kaspar, Tsymbalyuk, Orest, Semick, Stephen, Moyer, Mitchell, Negoita, Serban, Kim, Kevin, Ivanova, Svetlana, Gerzanich, Volodymyr, Simard, J. Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665704/
https://www.ncbi.nlm.nih.gov/pubmed/33186383
http://dx.doi.org/10.1371/journal.pone.0242427
_version_ 1783610023294795776
author Keledjian, Kaspar
Tsymbalyuk, Orest
Semick, Stephen
Moyer, Mitchell
Negoita, Serban
Kim, Kevin
Ivanova, Svetlana
Gerzanich, Volodymyr
Simard, J. Marc
author_facet Keledjian, Kaspar
Tsymbalyuk, Orest
Semick, Stephen
Moyer, Mitchell
Negoita, Serban
Kim, Kevin
Ivanova, Svetlana
Gerzanich, Volodymyr
Simard, J. Marc
author_sort Keledjian, Kaspar
collection PubMed
description BACKGROUND: Gulf War (GW) Illness (GWI) is a debilitating condition with a complex constellation of immune, endocrine and neurological symptoms, including cognitive impairment, anxiety and depression. We studied a novel model of GWI based on 3 known common GW exposures (GWE): (i) intranasal lipopolysaccharide, to which personnel were exposed during desert sand storms; (ii) pyridostigmine bromide, used as prophylaxis against chemical warfare; and (iii) chronic unpredictable stress, an inescapable element of war. We used this model to evaluate prophylactic treatment with the PPARγ agonist, rosiglitazone (ROSI). METHODS: Rats were subjected to the three GWE for 33 days. In series 1 and 2, male and female GWE-rats were compared to naïve rats. In series 3, male rats with GWE were randomly assigned to prophylactic treatment with ROSI (GWE-ROSI) or vehicle. After the 33-day exposures, three neurofunctional domains were evaluated: cognition (novel object recognition), anxiety-like behaviors (elevated plus maze, open field) and depression-like behaviors (coat state, sucrose preference, splash test, tail suspension and forced swim). Brains were analyzed for astrocytic and microglial activation and neuroinflammation (GFAP, Iba1, tumor necrosis factor and translocator protein). Neurofunctional data from rats with similar exposures were pooled into 3 groups: naïve, GWE and GWE-ROSI. RESULTS: Compared to naïve rats, GWE-rats showed significant abnormalities in the three neurofunctional domains, along with significant neuroinflammation in amygdala and hippocampus. There were no differences between males and females with GWE. GWE-ROSI rats showed significant attenuation of neuroinflammation and of some of the neurofunctional abnormalities. CONCLUSION: This novel GWI model recapitulates critical neurofunctional abnormalities reported by Veterans with GWI. Concurrent prophylactic treatment with ROSI was beneficial in this model.
format Online
Article
Text
id pubmed-7665704
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-76657042020-11-18 The peroxisome proliferator-activated receptor gamma (PPARγ) agonist, rosiglitazone, ameliorates neurofunctional and neuroinflammatory abnormalities in a rat model of Gulf War Illness Keledjian, Kaspar Tsymbalyuk, Orest Semick, Stephen Moyer, Mitchell Negoita, Serban Kim, Kevin Ivanova, Svetlana Gerzanich, Volodymyr Simard, J. Marc PLoS One Research Article BACKGROUND: Gulf War (GW) Illness (GWI) is a debilitating condition with a complex constellation of immune, endocrine and neurological symptoms, including cognitive impairment, anxiety and depression. We studied a novel model of GWI based on 3 known common GW exposures (GWE): (i) intranasal lipopolysaccharide, to which personnel were exposed during desert sand storms; (ii) pyridostigmine bromide, used as prophylaxis against chemical warfare; and (iii) chronic unpredictable stress, an inescapable element of war. We used this model to evaluate prophylactic treatment with the PPARγ agonist, rosiglitazone (ROSI). METHODS: Rats were subjected to the three GWE for 33 days. In series 1 and 2, male and female GWE-rats were compared to naïve rats. In series 3, male rats with GWE were randomly assigned to prophylactic treatment with ROSI (GWE-ROSI) or vehicle. After the 33-day exposures, three neurofunctional domains were evaluated: cognition (novel object recognition), anxiety-like behaviors (elevated plus maze, open field) and depression-like behaviors (coat state, sucrose preference, splash test, tail suspension and forced swim). Brains were analyzed for astrocytic and microglial activation and neuroinflammation (GFAP, Iba1, tumor necrosis factor and translocator protein). Neurofunctional data from rats with similar exposures were pooled into 3 groups: naïve, GWE and GWE-ROSI. RESULTS: Compared to naïve rats, GWE-rats showed significant abnormalities in the three neurofunctional domains, along with significant neuroinflammation in amygdala and hippocampus. There were no differences between males and females with GWE. GWE-ROSI rats showed significant attenuation of neuroinflammation and of some of the neurofunctional abnormalities. CONCLUSION: This novel GWI model recapitulates critical neurofunctional abnormalities reported by Veterans with GWI. Concurrent prophylactic treatment with ROSI was beneficial in this model. Public Library of Science 2020-11-13 /pmc/articles/PMC7665704/ /pubmed/33186383 http://dx.doi.org/10.1371/journal.pone.0242427 Text en © 2020 Keledjian et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Keledjian, Kaspar
Tsymbalyuk, Orest
Semick, Stephen
Moyer, Mitchell
Negoita, Serban
Kim, Kevin
Ivanova, Svetlana
Gerzanich, Volodymyr
Simard, J. Marc
The peroxisome proliferator-activated receptor gamma (PPARγ) agonist, rosiglitazone, ameliorates neurofunctional and neuroinflammatory abnormalities in a rat model of Gulf War Illness
title The peroxisome proliferator-activated receptor gamma (PPARγ) agonist, rosiglitazone, ameliorates neurofunctional and neuroinflammatory abnormalities in a rat model of Gulf War Illness
title_full The peroxisome proliferator-activated receptor gamma (PPARγ) agonist, rosiglitazone, ameliorates neurofunctional and neuroinflammatory abnormalities in a rat model of Gulf War Illness
title_fullStr The peroxisome proliferator-activated receptor gamma (PPARγ) agonist, rosiglitazone, ameliorates neurofunctional and neuroinflammatory abnormalities in a rat model of Gulf War Illness
title_full_unstemmed The peroxisome proliferator-activated receptor gamma (PPARγ) agonist, rosiglitazone, ameliorates neurofunctional and neuroinflammatory abnormalities in a rat model of Gulf War Illness
title_short The peroxisome proliferator-activated receptor gamma (PPARγ) agonist, rosiglitazone, ameliorates neurofunctional and neuroinflammatory abnormalities in a rat model of Gulf War Illness
title_sort peroxisome proliferator-activated receptor gamma (pparγ) agonist, rosiglitazone, ameliorates neurofunctional and neuroinflammatory abnormalities in a rat model of gulf war illness
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665704/
https://www.ncbi.nlm.nih.gov/pubmed/33186383
http://dx.doi.org/10.1371/journal.pone.0242427
work_keys_str_mv AT keledjiankaspar theperoxisomeproliferatoractivatedreceptorgammappargagonistrosiglitazoneamelioratesneurofunctionalandneuroinflammatoryabnormalitiesinaratmodelofgulfwarillness
AT tsymbalyukorest theperoxisomeproliferatoractivatedreceptorgammappargagonistrosiglitazoneamelioratesneurofunctionalandneuroinflammatoryabnormalitiesinaratmodelofgulfwarillness
AT semickstephen theperoxisomeproliferatoractivatedreceptorgammappargagonistrosiglitazoneamelioratesneurofunctionalandneuroinflammatoryabnormalitiesinaratmodelofgulfwarillness
AT moyermitchell theperoxisomeproliferatoractivatedreceptorgammappargagonistrosiglitazoneamelioratesneurofunctionalandneuroinflammatoryabnormalitiesinaratmodelofgulfwarillness
AT negoitaserban theperoxisomeproliferatoractivatedreceptorgammappargagonistrosiglitazoneamelioratesneurofunctionalandneuroinflammatoryabnormalitiesinaratmodelofgulfwarillness
AT kimkevin theperoxisomeproliferatoractivatedreceptorgammappargagonistrosiglitazoneamelioratesneurofunctionalandneuroinflammatoryabnormalitiesinaratmodelofgulfwarillness
AT ivanovasvetlana theperoxisomeproliferatoractivatedreceptorgammappargagonistrosiglitazoneamelioratesneurofunctionalandneuroinflammatoryabnormalitiesinaratmodelofgulfwarillness
AT gerzanichvolodymyr theperoxisomeproliferatoractivatedreceptorgammappargagonistrosiglitazoneamelioratesneurofunctionalandneuroinflammatoryabnormalitiesinaratmodelofgulfwarillness
AT simardjmarc theperoxisomeproliferatoractivatedreceptorgammappargagonistrosiglitazoneamelioratesneurofunctionalandneuroinflammatoryabnormalitiesinaratmodelofgulfwarillness
AT keledjiankaspar peroxisomeproliferatoractivatedreceptorgammappargagonistrosiglitazoneamelioratesneurofunctionalandneuroinflammatoryabnormalitiesinaratmodelofgulfwarillness
AT tsymbalyukorest peroxisomeproliferatoractivatedreceptorgammappargagonistrosiglitazoneamelioratesneurofunctionalandneuroinflammatoryabnormalitiesinaratmodelofgulfwarillness
AT semickstephen peroxisomeproliferatoractivatedreceptorgammappargagonistrosiglitazoneamelioratesneurofunctionalandneuroinflammatoryabnormalitiesinaratmodelofgulfwarillness
AT moyermitchell peroxisomeproliferatoractivatedreceptorgammappargagonistrosiglitazoneamelioratesneurofunctionalandneuroinflammatoryabnormalitiesinaratmodelofgulfwarillness
AT negoitaserban peroxisomeproliferatoractivatedreceptorgammappargagonistrosiglitazoneamelioratesneurofunctionalandneuroinflammatoryabnormalitiesinaratmodelofgulfwarillness
AT kimkevin peroxisomeproliferatoractivatedreceptorgammappargagonistrosiglitazoneamelioratesneurofunctionalandneuroinflammatoryabnormalitiesinaratmodelofgulfwarillness
AT ivanovasvetlana peroxisomeproliferatoractivatedreceptorgammappargagonistrosiglitazoneamelioratesneurofunctionalandneuroinflammatoryabnormalitiesinaratmodelofgulfwarillness
AT gerzanichvolodymyr peroxisomeproliferatoractivatedreceptorgammappargagonistrosiglitazoneamelioratesneurofunctionalandneuroinflammatoryabnormalitiesinaratmodelofgulfwarillness
AT simardjmarc peroxisomeproliferatoractivatedreceptorgammappargagonistrosiglitazoneamelioratesneurofunctionalandneuroinflammatoryabnormalitiesinaratmodelofgulfwarillness